Abstract：Objective: To investigate the effects of dagliprazin combined with glucagon-like peptide-1 (GLP-1) analogs on blood glucose fluctuation and ventricular remodeling in patients with diabetes mellitus and chronic heart failure. Methods: Ninety diabetic patients with chronic heart failure were randomly divided into two groups. The patients in the control group were treated with GLP-1 analogues, and the patients in the study group were treated with dapagliflozin combined with GLP-1 analogues. The efficacy, blood glucose fluctuation and ventricular remodeling were compared between the two groups. Results: Compared with the control group, the overall response rate was higher in the study group (P<0.05); before and after treatment, glycosylated hemoglobin (HbA1c), fasting plasma glucose (FPG), 2h postprandial plasma glucose (2hPG) levels, amplitude of blood glucose excursion (LAGE), mean absolute difference of daytime blood glucose (MODD), amplitude of postprandial blood glucose excursion (PPGE), standard deviation of blood glucose level (SDBG), left ventricular remodeling index (LVRI), left ventricular mass index (LVMI), left ventricular end diastolic diameter (LVEDD) and left ventricular ejection fraction (LVEF) differences were greater in the study group than in the control group (P<0.05). Conclusion: Dapagliflozin combined with GLP-1 analogues can reduce blood glucose fluctuation and improve ventricular remodeling in diabetic patients with chronic heart failure.
芦秋彤, 常欣, 巴丽丽, 柏静. 达格列净联合胰高糖素样肽-1类似物在糖尿病伴慢性心衰中的治疗效果观察[J]. 河北医学, 2023, 29(8): 1308-1312.
LU Qiutong, CHANG Xin, BA Lili, et al. Therapeutic Effect of Dagliflozin Combined with Glucagon-Like Peptide-1 Analog in Diabetes Mellitus with Chronic Heart Failure. HeBei Med, 2023, 29(8): 1308-1312.
[1] 国家卫生健康委员会能力建设和继续教育中心,孙艺红,陈康,等.糖尿病患者合并心血管疾病诊治专家共识[J].中华内科杂志,2021,60(5):17-18. [2] 王玉洁,徐鑫.达格列净对2型糖尿病合并心力衰竭患者血清心肌损伤标志物、左心室重构的影响[J].内科,2022,17(3):305-308. [3] Arbel R, Aboalhasan E, Hammerman A, et al. Dapagliflozin vs. sacubitril-valsartan for prevention of heart failure events in non-diabetic patients with reduced ejection fraction: a cost per outcome analysis[J]. Eur Prev Cardiol, 2021,28(15):1665-1669. [4] 张建军.接轨国际指南、彰显中国特色—《中国心力衰竭诊断和治疗指南2018》解读[J].中国临床医生杂志,2019,47(4):398-402. [5] 张雨瑶,俞瑞群,张家美.心力衰竭合并2型糖尿病的研究进展[J].中西医结合心脑血管病杂志,2022,20(20):3727-3729. [6] 张玲娟,王西辉,曹彪,等.芪苈强心胶囊联合达格列净对心力衰竭合并2型糖尿病患者血糖水平、神经内分泌因子及心功能的影响[J].临床医学研究与实践,2022,7(20):61-65. [7] 吴飞雪,漆洁.达格列净联合沙库巴曲缬沙坦治疗慢性心力衰竭合并2型糖尿病的效果及对血糖波动的影响[J].糖尿病新世界,2021,24(14):57-64. [8] 张冰,尚军洁.利拉鲁肽对老年糖尿病患者血糖水平、血清炎症因子、氧化应激及肠道菌群的影响[J].药学服务与研究,2021,21(6):404-454. [9] 邢巧琳,张庚良.利拉鲁肽联合降糖养心方治疗糖尿病心肌病疗效及对炎症因子的影响[J].现代中西医结合杂志,2022,31(21):2975-3001. [10] Arturi F, Succurro E, Miceli S, et al. Liraglutide improves cardiac function in patients with type 2 diabetes and chronic heart failure[J]. Endocrine,2017,57(3):464-473. [11] 陈静,顾崇怀,项学军,等.达格列净对冠心病合并2型糖尿病伴高血压患者的临床疗效观察[J].实用药物与临床,2022,25(7):595-600. [12] 陈静,李桂芳.MMP-14、MMP-13与慢性心力衰竭患者心室重构的关系[J].检验医学与临床,2022,19(15):2078-2081. [13] 刘静芹,何玉秀,张桂玲,等.利拉鲁肽对糖尿病的心肌保护效应及机制研究进展[J].中国新药与临床杂志,2016,35(9):625-630. [14] Brown AJM, Lang C, McCrimmon R, et al. Does dapagliflozin regress left ventricular hypertrophy in patients with type 2 diabetes A prospective, double-blind, randomised, placebo-controlled study[J]. BMC Cardiovasc Disord,2017,17(1):229.
2023, Vol. 29 
冀公网安备13080202000677号